Integrative proteogenomic methods use mass spectrometry (MS)-based proteomic database for identifying new genomic alterations and validating novel protein sequences as potential disease biomarkers or therapeutic targets. The customized database approach is time consuming and not feasible for real...
Built on a continuous partnership between National Cancer Institute’s (NCI’s) Cancer Imaging Program and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), NCI’s The Cancer Imaging Archive (TCIA) releases a newly improved CPTAC histopathology interface. The interface hosts histopathology i...
Built on a continuous partnership between National Cancer Institute (NCI) and the University of Victoria Genome British Columbia Proteomics Centre, NCI’s CPTAC Assay Portal releases 660 mouse multiple reaction monitoring-mass spectrometry (MRM-MS) plasma assays to the community.
The incidence of early-onset gastric cancer (EOGC), a type of cancer that occurs in younger patients and found throughout the stomach, is markedly elevated in the Republic of Korea. As a country with the highest rates worldwide in both sexes, there is a need to identify molecular signature...
Claudin-Low (CLOW) tumors are classified as a subset of triple-negative breast cancers and account for a minority of breast cancer cases. But until now, there has been little study of their unique biological features. Understanding the biology of CLOW tumors is important for designing targeted th...
The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just four days left to submit your computational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2. Than...
CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in Science Signaling, CPTAC investigat...
The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just two weeks left to submit your compuational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2.
The second data release for the NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge has launched! If you did not participate in sub-challenge 1 (submission 1), you can still participate in sub-challenge 2 (submission 2).
Several ongoing Phase I clinical trials are assessing the safety and tolerability of ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-Related) inhibitors when administered alone or in combination with existing therapies. ATM and ATR are attractive therapeutic targets in...
The security of precisionFDA users’ personal information and data is of critical importance. To strengthen the safeguards already in place, precisionFDA will be introducing several changes to achieve compliance with the FedRAMP and FISMA Moderate security standards. These changes will take effect...
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC). CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer biology....
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21 proteins that is specialized for repairing DNA inter-strand cross-links. Identification of mono...
The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of a video titled, “International Cancer Proteogenome Consortium (ICPC)”. Launched during the 2018 Human Proteome Organization World Congress,...
The National Cancer Institute in partnership with the Food and Drug Administration is pleased to announce the launch of the precisionFDA NCI-CPTAC Multi-Omics Challenge. The aim of this crowd-sourced, cloud-based data challenge is to incentivize the development and evaluation of novel computation...
Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to understanding the molecular basis of disease and accelerating the translation of new discoveries to pati...
Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and o...
In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample transfe...
In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective dr...
Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new AML cases will occur in the United States this year.